"It's really cool. I know that doesn't sound technical or scientific, but when we saw the animal data we were ecstatic."

— Craig Adams, CEO of Valor Medical (San Diego), discussing the firm's new Neucrylate product, "Glue-like substance may offer improved aneurysm treatment," pp. 1, 6.